|
June 14, 2004
Ithaca, NY, USA
Transonic Systems Inc., global manufacturer of biomedical flow measurement equipment, announces the sale of ten
Flow-QC Hemodialysis Monitoring Systems (HD02) to the National Kidney Foundation of Singapore (NKFS). These Transonic Flow-QC Monitors will enhance the quality of care for
NKFS’ hemodialysis patients by enabling routine screening for vascular access patency, dialysis adequacy and cardiac output during their hemodialysis treatments.
This sale attests to Transonic’s worldwide leadership as supplier of gold-standard access patency management
tools. The HD02 system is recognized as the access patency measurement device of choice, with over 400 clinical publications citing use of the system to improve
hemodialysis care.
Transonic’s Singapore distributor, Transmedic PTA, established NKFS to ensure adoption of the hemodialysis
monitoring throughout Asia. Singapore’s NKFS dialysis clinics will serve as Centers for Excellence, modeling exemplary vascular access surveillance for other Asian
countries.
NKFS has introduced Transonic Flow-QC Hemodialysis Monitoring as standard practice in their 20 dialysis centers.
Dr. Mooppil Nandakumar, head of dialysis services at NKFS comments: “the integration of the access flow monitoring systems from Transonic into our dialysis clinics allows
us to provide the high quality of care for our patients. It will assist us in detecting vascular access stenosis so that we could do early intervention. This will prevent
thrombotic events, prolong the life of vascular accesses and increase patient satisfaction.”
For hemodialysis patients, their vascular access is their link to life. This surgically created connection
between an artery and vein enables access to a patients’ blood for cleansing during hemodialysis. A vascular access often narrows (stenoses) and can shut down completely
resulting in hospitalization of the patient. Medicare costs in the United States alone exceed for treating access problems exceed $1 billion annually.
Transonic’s Flow-QC Monitor has given nephrologists a new tool to follow the progression of stenotic disease
within the vascular access. The dialysis staff can then proactively intervene to extend the life of the access with outpatient procedures rather than major surgery.
Cornelis Drost, Transonic Systems’ president, states “We are proud of our role in reducing the necessity for
hospitalizations for hemodialysis patients and advancing the continued improvement in quality of care.”
For more information please contact:
Mark Emley
Transonic Systems Inc.
800-353-3569
Mark.Emley@transonic.com
|
